Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
Jazz Pharmaceuticals (Nasdaq: JAZZ) will report fourth quarter and full year 2025 financial results on February 24, 2026 after the close of U.S. markets.
Rhea-AI Summary
Jazz Pharmaceuticals (Nasdaq: JAZZ) will report fourth quarter and full year 2025 financial results on February 24, 2026 after the close of U.S. markets. Management will host a live webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss results and provide a business and financial update.
Interested parties may register in advance via the Investors section of the Jazz Pharmaceuticals website. A replay will be posted to the investor site for on‑demand access.
Positive
- None.
Negative
- None.
Details
News Market Reaction – JAZZ
On Feb 11, the first trading day after this news, JAZZ closed 0.37% above the previous close.
Data tracked by StockTitan Argus for the Feb 11 session.
Key Figures
- Earnings date
- February 24, 2026
- Q4 and full-year 2025 results release after U.S. market close
- Webcast time ET
- 4:30 p.m. ET
- Management webcast to discuss Q4 and 2025 results
- Webcast time GMT
- 9:30 p.m. GMT
- Same earnings results webcast in GMT
- Registration lead time
- 15 minutes
- Recommended minimum early registration before scheduled webcast
Historical Context
-
Quarterly cash distribution declaration and key record/payment dates.
-
Appointment of Thomas Riga as Chief Business Officer with deal-making track record.
-
Positive Phase 3 HERIZON-GEA-01 results for Ziihera in HER2+ GEA.
-
Planned webcasts for clinical updates and J.P. Morgan conference presentation.
-
Dec 09
Clinical data update
- 24h Move
- -4.0%
Positive Xywav Phase 4 DUET and real-world data presentations at major meetings.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
Contacts:
Investors:
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
Media:
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-on-tuesday-february-24-2026-302684128.html
SOURCE Jazz Pharmaceuticals plc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.